Skip to content
Home/Companies/Biotech/A3P Biomedical

A3P Biomedical

Biotech·Sweden·Exited 2025·Held 3yr
Entry
2022
Hold
3yr
Exit
2025

Who owns A3P Biomedical?

A3P Biomedical was owned by Flerie through Flerie Invest (2011 vintage) from 2022 to 2025, exited via Secondary.

Hand-verified · updated 2026-08-17

Flerie
Investor
Flerie
Flerie Invest · 2011 · Life Sciences VC

Key facts

HQSweden
SectorBiotech
StatusAcquired
Exit Type
Secondary
Buyer
–
MOIC
–
Exit Year
2025

More from Flerie Invest

Other portfolio companies in the same fund.

Frontier Biosolutions
Active
PharmaGermany· 2023
Mendus
Active
BiotechSweden· 2023
Alder Therapeutics
Active
BiotechSweden· 2022
AnaCardio
Active
BiotechSweden· 2022
Bohus Biotech
Active
PharmaSweden· 2022
Geneos Therapeutics
Active
BiotechUS· 2022

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS
Track A3P Biomedical

Save this record to your watchlist and pick up your research where you left off. No spam.

Create free account

Who could buy A3P Biomedical?

7 strategic and 113financial buyers match this company's sector and geography profile, ranked from verified European deal history.

Find likely buyers

Get the full record on A3P Biomedical.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Hand-checked deal notes on this investment
Save this company to your watchlist
Exit buyer and MOIC on this deal (Pro)
or
Continue with email

Already a member? Sign in

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue